X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Elahere (mirvetuximab soravtansine) is a first-in-class antibody-drug conjugate (ADC) approved for folate receptor alpha (FRα) positive platinum-resistant ovarian cancer.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
RDD 2024
Not Confirmed
Contact Supplier
Details:
The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space by including Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for FRα positive platinum-resistant ovarian cancer (PROC).
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $10,100.0 million Upfront Cash: $10,100.0 million
Deal Type: Acquisition February 12, 2024
RDD 2024
Not Confirmed
Contact SupplierDetails:
Elahere (mirvetuximab soravtansine-gynx) is an ADC. The antibody is a chimeric IgG1 directed against folate receptor alpha and DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. It is being developed for FRα-positive platinum-resistant ovarian cancer.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
RDD 2024
Not Confirmed
Contact SupplierDetails:
Under the agreement, ImmunoGen has retained production rights and will supply product for development and commercial use in Japan and Takeda will receive license to develop and commercialize ELAHERE in Japan and is responsible for all regulatory filings and obligations.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $34.0 million
Deal Type: Collaboration August 28, 2023
RDD 2024
Not Confirmed
Contact SupplierDetails:
ImmunoGen intends to use the proceeds to fund its operations, including global commercialization activities, supply of ELAHERE® (mirvetuximab soravtansine-gynx) drug product, pipeline research and development activities, business development, and capital expenditures.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $373.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 09, 2023
RDD 2024
Not Confirmed
Contact SupplierDetails:
ImmunoGen intends to use the net proceeds to fund its operations, including, but not limited to, global commercialization activities, supply of ELAHERE® (mirvetuximab soravtansine-gynx) drug product, clinical trial activities, pipeline research and development activities.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $325.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 04, 2023
RDD 2024
Not Confirmed
Contact SupplierDetails:
Elahere (mirvetuximab soravtansine-gynx) is an ADC. The antibody is a chimeric IgG1 directed against folate receptor alpha and DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. It is being developed for FRα-positive platinum-resistant ovarian cancer.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
RDD 2024
Not Confirmed
Contact SupplierDetails:
In the intent-to-treat population, statistically significant improvement in number of patients achieving 15-point improvement in gastrointestinal symptoms was observed at week 8/9 in patients treated with IMGN853 (mirvetuximab) versus chemotherapy (31.7% vs 14.0% P = 0.0162).
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2022
RDD 2024
Not Confirmed
Contact SupplierDetails:
Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, to kill the targeted cancer cells.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
RDD 2024
Not Confirmed
Contact SupplierDetails:
Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, to kill the targeted cancer cells.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
RDD 2024
Not Confirmed
Contact SupplierDetails:
SORAYA Trial for IMGN853 (mrvetuximab soravtansine), first-in-class ADC comprising a folate receptor alpha-binding antibody met primary endpoint with confirmed objective response rate of 32.4%, including 5 complete responses; updated median duration of response of 6.9 months.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2022
RDD 2024
Not Confirmed
Contact SupplierDetails:
Pivotal SORAYA Trial of IMGN853 (Mirvetuximab Soravtansine) met Primary Endpoint with Confirmed Objective Response Rate of 32.4%.in patients with folate receptor alpha (FR?)-high platinum-resistant ovarian cancer.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
RDD 2024
Not Confirmed
Contact SupplierDetails:
Partnership accelerates development path for Mirvetuximab in Greater China and expands Huadong Medicine’s oncology portfolio with innovative ADC.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hangzhou Huadong Medicine Group Kangrun Pharmaceutical
Deal Size: $305.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration October 19, 2020
RDD 2024
Not Confirmed
Contact SupplierDetails:
The funds raised balances Company’s sheet and will support clinical trial activities, supply of drug substance and drug product, pre commercialization and commercialization activities, capital, expenditures, and working capital.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 12, 2020
RDD 2024
Not Confirmed
Contact SupplierDetails:
Mirvetuximab was readily combined and well tolerated with standard dosing of carboplatin and bevacizumab, with a manageable adverse event (AE) profile as anticipated for this triplet based on the side effect profiles of each agent.
Lead Product(s): Mirvetuximab Soravtansine,Carboplatin,Bevacizumab
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
RDD 2024
Not Confirmed
Contact SupplierDetails:
The combination of mirvetuximab soravtansine with bevacizumab in this cohort demonstrates encouraging anti-tumor activity with a favorable tolerability profile, particularly among the subset of patients with high levels of FRα expression.
Lead Product(s): Mirvetuximab Soravtansine,Bevacizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
RDD 2024
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
